Objectives: Vaccinations protect children against deadly diseases and approximately 30 immunizations are recommended for children by 6 years of age. However, immunization injections cause negative short-term and long-term consequences for children. The Gate Control Theory of pain suggests that physical interventions (eg, rubbing the site) may be helpful, but they are not well validated for children's acute pain. This randomized trial examined the effectiveness of the ShotBlocker, a physical intervention designed to decrease children's injection pain.
C hildhood immunizations are a priority for the pediatric patient and the general public; however, pain resulting from these needle injection results in short-term and longterm negative repercussions for the child. The immediate impact is high levels of fear, anxiety, and pain during the medical visit; and long-term outcomes include potential elevated distress during upcoming procedures and avoidance of future healthcare. 1 To counter the issues noted, pain management has included pharmacological (eg, topical anesthetics), behavioral (eg, distraction), and physical approaches (eg, massage). Pharmacological and behavioral treatments have received significant attention, whereas physical approaches have received less attention. 1 Physical interventions, involving direct stimulation of the area near the noxious stimulus, include massage, touching, rubbing, acupuncture, and transcutaneous electrical nerve stimulation. 2 The Gate Control Theory of pain 3 offers a theoretical explanation of how physical interventions might reduce pain. The theory suggests that pain is transmitted from the peripheral nervous system to the central nervous system where it is modulated by a gating system in the dorsal horn of the spinal cord. Non-noxious physical stimulation-such as rubbing, massage, and vibration-activates the fast, large diameter, myelinated nerve fibers (A-b) and inhibits the transmission (closes the gate) of pain, which travels via the afferent pain-receptive nerves (A-d and C fibers).
One novel and inexpensive physical intervention is the ShotBlocker (manufactured by Bionix; Toldeo, OH), a small, flat u-shaped plastic device, measuring approximately 70 mm by 50 mm across at its widest points and 2 mm thick, with rounded nubs to stimulate the skin around the site of the injection (Fig. 1) . The device potentially provides more consistent stimulation than techniques such as pressing, pinching, or stretching. Theoretically, the pressing down of the nubs on the skin should stimulate A-b signals, which inhibit the A-d and C fiber pain transmission of the injection, consistent with the Gate Control Theory. 3 Although conceptually sound, there are a few data in support of the manufacturer's claim that the ShotBlocker ''blocks the pain of minor injections without the use of chemical refrigerant sprays or drug based creams.'' 4 To date, there are 4 studies available, which have evaluated the ShotBlocker. Two of these studies, found on the Bionix website, support the efficacy of the ShotBlocker. 5, 6 The unpublished study by Gundrum et al 6 is available only in a brief abstract form. Ninty-nine patients enrolled for the study over the age of 5 years (specific ages were not presented), who were randomized to receive immunizations with or without the ShotBlocker. The authors reported significantly reduced pain in the intervention group; however, specific details of method (eg, randomization, procedure), statistics, or results were not provided. It seems that child self-report of pain was the exclusive dependent variable. An unpublished study conducted by Guevarra, 5 also presented only in abstract form, included 119 prekindergarten students in the Philippines who were receiving intramuscular injections. Participants in the treatment group reported significantly lower pain scores on the Wong-Baker Faces Pain Rating Scale. 7 Similar to the previous study, no measure of behavioral pain or observer report was examined, no placebo group was included, and additional information about methodology is limited.
The remaining 2 studies do not provide evidence that the ShotBlocker is an effective intervention to reduce children's immunization pain. Drago et al 8 evaluated the device with 165 2-month-old to 17-year-old participants. Parents and nurses rated participants' pain on a 6-point Likert scale and children over 36 months of age provided self-report using the Wong-Baker Faces Pain Rating Scale. 7 Parents and nurses rated children's pain lower when using the ShotBlocker; however, there were no significant group differences in children's self-reported pain. Unfortunately, this study was only presented as a conference poster and additional details about design and procedure (eg, randomization) are not available. The fourth study, printed in a nursing research newsletter, 9 detailed a 2-group, randomized, controlled research study that included a diverse sample of 171 children between the ages of 3 months and 17 years. Parents and children old enough to provide selfreported pain ratings rated children's pain using the Faces Pain Scale-Revised. 10 There were no significant differences in pain ratings between the experimental and control group. 9 Given the paucity and mixed results available and that no data have appeared in a peer-reviewed publication, a more thorough evaluation of the ShotBlocker's effectiveness is in order.
SUMMARY AND PURPOSE
In summary, immunization injections cause multiple negative short-term and long-term consequences for children. The Shotblocker is an inexpensive and easy-to-use device that might mitigate children's injection pain. Theoretically, the device should stimulate nerve receptors that interfere with pain processing. The purpose of this study was to provide a thorough evaluation the ShotBlocker. On the basis of theoretical underpinnings and the results of the 2 abstracts, 5, 6 it was hypothesized that the ShotBlocker would result in significantly lower pain scores on child selfreport, parent-report, nurse-report, behavioral observation, and physiologic measures in comparison with both typical care control and placebo control. A secondary expected finding was that placebo would provide small, but statistically significant, reductions in pain.
MATERIALS AND METHODS

Participants
Participants included 89 parent-child dyads presenting for pediatric immunization injections at a southeastern pediatric practice in the Metro-Atlanta area between March 2006 and July 2006. The children ranged from 4 to 12 years of age (M = 8.46 y, SD = 2.97 y). Children younger than the age of 4 were not included, because they would not likely be able to provide valid self-report ratings of pain. Children up to 12 years of age were included to increase external validity in applying findings to school-aged children. Using the effects size of 1.18 found in a prior study of the ShotBlocker, 5 a power analysis with power of 0.87 revealed that only 12 participants would be needed to detect differences using a 3-group analysis of variance (ANOVA). However, given the prior mixed findings, a more conservative sample of 30 participants per condition was deemed sufficient to find treatment effects. Inclusion criteria included any 4-to 12-year-old English-speaking child receiving inoculations at the clinic.
Fifty-two of the child participants were male (58.2%) and 76 were White (85.4%). Five children were African American (5.6%), 1 child was Asian American (1.1%), and 7 children were reported as ''mixed'' or ''other'' by their parents (7.8%). Children primarily came from 2-parent homes with 79 parents (88.8%) indicating they were married. Seven parents (7.8%) indicated they were separated or divorced and 2 parents (2.2%) reported that they were single. All children enrolled in the study were accompanied by either their mother (75, 84.3%) or father (14, 15.7%). Parents ranged in age from 28 to 59 years of age (M = 40.2 y, SD = 5.7 y); however, 3 parents chose not to report their date of birth. The parents' years of education ranged from 12 to 23 years (M = 15.78 y, SD = 1.74 y). The majority of families (78, 60.3%) reported annual income of $90,000 or greater.
Approximately, half of the sample (50.5%) received only one injection, 17 children (18.3%) received 2 injections, 14 children received 3 injections (15.1%), and 9 children received 4 injections (10.3%). Researchers did not record the type of immunization or whether the injections were subcutaneous or intramuscular.
Measures
Background Information
Parents who agreed to participate in the study completed a questionnaire assessing demographics of both the child and parent to provide descriptive information about the sample so that external validity might be assessed and to evaluate whether variables potentially influencing pain experiences and perceptions were equally distributed across the 3 conditions (ie, whether randomization was successful). The child's sex, age, race, and family income were included as part of the demographics questionnaire. The parent also answered questions regarding any medical conditions that would require regular injections; any pain-reducing medications the child may have received before the procedure (eg, acetaminophen); and if, when, and how the child was informed of receiving an injection. In addition, the parents were queried as to whether or not the child was born premature, and if so whether the child received neonatal intensive care.
Child Distress
Children rated their pain both preinjection and postinjection using the using the Faces Pain Scale-Revised, 10 which is a modified version of the original Faces Pain Scale 11 and contains 6 cartoon faces expressing no pain to extreme pain and scored from 0 to 10. The faces are presented to the child, who is told, ''These faces show how much pain a child can feel. This face (point to face) shows no pain. The faces show more and more pain up until this one (point to face). It shows very much pain.'' The child is then asked to select a face that represents either their current level of pain or level of pain during the injection. This measure was designed to create minimal cognitive demands on the child, thus making it appropriate for children of young ages. Research has shown that this measure has adequate reliability and validity. 10 However, because the sample included children as young as 4 years old, children who rated their preinjection level of pain as a 4 or higher were not included in postinjection pain ratings, given that they likely did not understand the measure or were possibly reporting high level of anxiety in addition to physical pain. Ten child postinjection ratings were excluded for this reason.
In addition to the children's indication of their pain, parents rated their children's injection pain and anxiety using a Visual Analog Scale (VAS). These measures consisted of 100 mm horizontal lines with anchor descriptors at either end of the continuum (eg, ''no pain'' and ''severe pain''). Parents were asked to draw a vertical mark on the continuum to rate their child's pain in response to the question, ''How much pain did your child experience during the injection?'' and anxiety in response to the question, ''How much anxiety did your child experience during the injection?'' This measure has been shown to be valid and reliable for both children and adults and is commonly used in pain research. 12 After the injection, the health-care provider also rated the pain and anxiety of the children using a similar VAS.
Children's distress was also assessed via heart rate. Research has supported the use of heart rate as a physiologic measure of pain, showing decreased heart rate when analgesics were administered and decreased heart rate as a result of behavioral interventions. 13 In addition, heart rate is recommended because of its ease of use and noninvasive nature. 13 That said, it should be noted that heart rate is reactive to emotional state, movement, room temperature, and other factors besides pain. 13, 14 A small electronic monitor, the Tanita Cardio (Tanita Corporation of America Inc, Arlington Heights, IL) was used to take an electronic reading of the children's heart rate at baseline and then immediately after the injection. The precision is ± 5% for pulses between 30 and 200 beats per minute. Each child's change in heart rate from baseline to postinjection served as the physiologic measure of distress.
Finally, children's distress was coded using 3 relevant behavioral indicants of distress. The behaviors were consistent with those used and validated in other behavioral scales (eg, Child-Adult Medical Procedure Interaction Scale 15 ; the Observational Scale of Behavioral Distress 16 ). The behaviors were: crying, screaming, and adult restraint. Initially, coders were trained to code using videotape data from a prior study. Once interrater agreement had been achieved (ie, Cohen's Kappa of 0.80), coding of study data commenced. Coders remained blind to study hypotheses and spanned from 3 minutes before the nurse prepping the injection site by wiping it with alcohol until 3 more minutes after the final needle was removed. To examine differences across phases of the procedure, a total observational distress composite (combining all 3 behavioral codes) was calculated, and behavioral scores for preinjection (3 min before until cleaning of the site), injection (cleaning of the site until the needle was removed), and postinjection (removal of the needle until 3 min later). The behaviors were coded for occurrence in 5-second intervals. Ratio of distress behavior was calculated by dividing the number of intervals of distress by the total number of intervals. Interrater reliability for coding in this study was 93.6% agreement for crying, 98.4% agreement for screaming, and 95.2% agreement for adult restraint of the child.
Procedure
The study procedure and its informed consent form were approved by the Georgia State University Institutional Review Board. This study was designed in accord with, and adheres to the guidelines detailed in the Consolidated Standards of Reporting Trials statement [17] [18] [19] ( Fig. 2 for the Consolidated Standards of Reporting Trials Flowchart). Eligible participants were typically approached in the exam room between checking in with the nurse and visiting with the pediatrician. Research assistants described the study to parents and obtained parent consent and child assent from those interested in participating. The informed consent explained the randomization process for group assignment. Parents and children were told that random assignment, similar to drawing straws, was carried out by computer ahead of time. In 2 of the groups a small plastic device would be put on the child's arm and the third group would the typical care usually administered by the staff. They were also informed that of the 2 ShotBlocker groups, one was a placebo group and they would not know until the end of the study, which group they were assigned.
With the help of the research assistant, the parent completed the demographics questionnaire. The research assistant also measured the baseline heart rate of both the parent and child. Participants were randomly assigned either to the typical care control (Typical Care Control), to the placebo control (Placebo Control), or to the ShotBlocker condition. The randomization was determined before the study via a random number table generated by the RanSL computer program. 20 Once participants completed all preinjection measures, the research assistant opened an envelope, which contained the participant condition assignment. Consistent with the explanation provided in the consent form, the parent(s) and child were only told if they were in the typical care group or one of the 2 ShotBlocker groups.
After the family had finished visiting with the pediatrician, the researcher reentered the exam room and set up the video camera, which was used to collect data for observational coding. Before leaving the room, the research assistant began recording, with the video camera focused on the exam table where injections were administered. The research assistant privately informed the nurse of the assigned condition so that the nurse was aware of the proper group protocol to follow.
ShotBlocker
Participants in the ShotBlocker condition received the intervention according to protocol. The nurse used the following script to introduce and describe the ShotBlocker:
''(Nurse shows child device). This is called the ShotBlocker.
It is used to help make shots hurt less. I am going to hold it against your arm like this (nurse demonstrates on own arm) while I give you your shot. It doesn't hurt at all. Would you like to hold it and see what it feels like? Now I will show you how it feels on your arm.'' (Nurse demonstrates on child's arm. If child is in the ShotBlocker group, press the device with nubs against skin. If child is in Placebo control, press the device with smooth side against the skin.) Once the nurse was prepared to administer the injection, she/he pressed the ShotBlocker firmly against the child's skin at the injection site with the raised nubs in direct contact with the child's skin. The device was placed on the child's arm for no more than 20 seconds before the injection and held in place until the injection was complete.
Placebo Control
Participants assigned to the placebo control group received the same scripted introduction to the medical device that was used with the ShotBlocker condition participants. They were not aware that they were assigned to the placebo control group. The health care provider placed the ShotBlocker on the child's arm with the smooth side against the child's skin, opposite as prescribed. This prevented the small rounded nubs from contacting the child's skin. The purpose of this condition was to test for any placebo effect (eg, child or parent expectancy the device might have in reducing the child's experienced pain and anxiety).
Typical Care Control
The typical care control group received treatment as usual and the health care provider was asked to administer the intramuscular injection without the use of the ShotBlocker. No other instructions or guidance about pain management were provided to the health care provider.
In all 3 conditions and immediately after the injection, the health care provider obtained child heart rate. The research assistant reentered the exam room after the procedure to turn off the video camera and assist the parent and child with postinjections forms After all forms were completed, children and parents who participated in the Placebo group were debriefed and told that they were part of the placebo control group, and then the research assistant demonstrated the correct use of the ShotBlocker device with the nubby side against the skin. Participants in the placebo control and ShotBlocker groups were allowed to keep their ShotBlocker to use for future injections. All children 
RESULTS
To ensure that randomization resulted in equivalent groups, an ANOVA was used to compare the 3 conditions (Typical Care Control, Placebo, and ShotBlocker) on child age and number of injections received and revealed no significant group differences (Table 1) . Chi-square analyses indicated no differences between groups on child sex, race, history of Neonatal Intensive Care Unit hospitalization, or existing medical condition that requires extra blood drawn through injections or through intravenously (Table 1) . Thus, random assignment successfully balanced potentially relevant factors across the 3 groups.
The next set of preliminary analyses examined bivariate correlations among demographic variables, specifically age, sex, and ethnicity, to determine whether considerations (eg, covariates or interactions) of these variables would be needed in subsequent analyses. Results revealed inverse correlations between child's age and all ratings of child pain and anxiety (eg, child-report, caregiver-report, and nursereport) and observational coding of child distress (Table 2) except heart rate change. ANOVAs revealed that ethnicity and sex were not related to measures of child distress. Child self-report ratings of injection pain were excluded if the child reported a preinjection rating of 4 or higher (on a scale of 0 to 10). Ten child postinjection ratings were excluded for this reason.
Means and SDs for all pain scores by condition are presented in Table 3 . An analysis of covariance was used to examine the main effect of treatment condition, while controlling for the child's age and also tested for a potential interaction between treatment condition and child age. Child age continued to predict child pain and anxiety on each dependent variable, except the physiologic measure of change in child heart rate; however, treatment condition was not significant for any of the dependent variables, nor were there any significant interactions (Table 4) .
A 3 (phase) Â 3 (group) repeated measures analysis of covariance was used to examine observational distress while controlling for child age and example potential interactions. A similar pattern emerged, with a significant main effect for child age. Additionally, there was a significant main effect for observational distress during the 3 phases of the procedure. The least significant difference post-hoc test indicated that the injection phase distress was higher than both preinjection and postinjection. Further, children had significantly more observational distress during the postinjection than the preinjection phase irrespective of condition. There was no main effect of treatment conditions for observational distress, for the phase Â condition interaction, or phase Â -condition Â child age interaction (Table 4) .
DISCUSSION
Effectiveness of ShotBlocker
This study evaluated the ShotBlocker, a physical intervention designed to decrease injection pain in children. The hypotheses of this study were not supported in that the results revealed no significant differences treatment effects in child distress on self-report, parent-report, nurse-report, heart-rate change, or observational scale indices. Significant phase differences suggest that the behavioral coding was sensitive to pediatric distress.
The Gate Control Theory suggests that the ShotBlocker should interfere with the ascending pain signal; however, results did not support the hypothesis. It could be that this particular physical intervention did not stimulate the nerves as intended and thus was not sufficiently effective to reduce children's immunization pain. In could also be that this physical intervention does provide a competing ascending signal to the brain, but that the descending cognitive/ emotional factors, such as negative expectations or preprocedural anxiety, override any interference caused by the physical intervention. In fact, the descending cognitive/ emotional factors may have been influenced by discussing the ShotBlocker device, which might have focused children's attention to the upcoming injection. Another explanation for the lack of effects is that the nurses or parents might have become overly reliant on the supposed benefits of the ShotBlocker and foregone distraction or other coaching, which have been shown to be beneficial. 21 In fact, there are data showing that nurses provide less distraction when a topical anesthetic is used for pediatric pain relief. 22 Previous research evaluating the ShotBlocker is limited and mixed regarding the effectiveness of the device in reducing children's immunization pain. 5, 6, 8, 9 Given that the prior studies were not published in peer-reviewed journals and they contain little information about methodology, it is difficult to reconcile any differences. At this point, it is clear that there are not sufficient data to support spending time, money, and energy on the ShotBlocker. It is important to disseminate information of this sort lest well-intentioned nurses waste resources on an intervention that is not validated and forgo other methods that have considerable support (eg, distraction).
1,23
Limitations and Future Directions
There are several caveats to consider when interpreting the results. The sample was homogenous in terms of class and race, with a primarily White sample and more than half the sample reporting a family income greater than $90,000 annually. Although a homogeneous sample increases internal validity, it raises questions regarding the generalizability of these findings to children of different ethnicities and lower social economical classes. This is especially pertinent given discrepancies in these findings and those with a sample from the Philippines. 5 Another limitation of the study was the wide age range of the sample, 4 to 12 years of age, because there is a great deal of variability in prior immunization experiences in children of different ages, which likely impacts their level of distress. However, analyses suggested age was randomized successfully across treatment conditions. It is possible that the ShotBlocker might be more effective for children who can understand the purpose of the device more easily, thus reducing their level of anxiety or other cognitive factors that could influence pain perception. Although findings from this study did not indicate that there is an age interaction, future researchers should consider comparing effectiveness of the ShotBlocker within circumscribed age groups.
Another limitation for the study was that both intramuscular and subcutaneous injections were included. Although this factor was randomized across conditions, there remains the possibility that the ShotBlocker is more effective for 1 needle injection and not another. Additional research of the ShotBlocker could answer this question. The potential influence of the nurse script, used in the ShotBlocker and Placebo conditions, is another important consideration. The script was provided to increase internal validity; however, it might have inadvertently heightened child's focus on the injection.
The setting for the study, a group practice pediatric office, had its advantages and disadvantages. For example, given that this was a busy pediatric practice, the staff might have hurried through the explanation of the device to the participants, which may have minimized potential placebo effect. In contrast, the medical setting provided a realistic evaluation of the effectiveness of the ShotBlocker in a reallife setting.
CONCLUSIONS
This study did not support the ShotBlocker as an effective intervention to reduce children's pain during immunization injections. Despite the lack of significant findings, this study contributes to the literature on physical interventions for pediatric pain. This study provided additional evidence that younger children experience high injection distress and might be in greater need for pain reduction interventions. As immunization injections are a common procedure for children and the distress children experience has both short-term and long-term consequences, it is important for researchers to continue evaluating and advocating for the implementation of effective pain management interventions. On balance, it is also important that research reveal when interventions are not effective lest practitioners spend time, money, and energy on interventions that do not provide benefit to the patient.
